DCVMN members are exploring several vaccine methods including: Both Inactivated and Live attenuated virus, DNA and RNA, viral vectors with capacity to replicate as well as non-replicating vectors, and  “recombinant protein sub-unit or virus-like particles.”

One member of DCVMN has been identified as testing the hypothesis of offering protection from the virus through the method of Bacille Calmette-Guérin (BCG) immune modulation. Testing is currently in clinical trials, and VPM1002, a recombinant BCG vaccine, is in phase 3.


Platforms being pursued for the vaccine

19 DCVMN members involved in R&D for 22 potential vaccines. Out of these, 4 members’ are executing Phase 1 or ½ of clinical trials, and the remaining vaccines were in the preclinical phase in May 2020.

Stanford University

Compilation of 2019 data, online research about COVID-19 vaccine activity by DCVMN organizations, and supply capacity surveys were used to analyze the potential of DCVMN member organizations in the following areas:
- Research, Development, and Technology
- Scaling
- Fill-finish and distribution
- Supply of other vaccines

Methods of Analysis of DCVMN

Pagliusi, S., Jarrett, S., Hayman, B., Kreysa, U., Prasad, S. D., Reers, M., Hong Thai, P., Wu, K., Zhang, Y. T., Baek, Y. O., Kumar, A., Evtushenko, A., Jadhav, S., Meng, W., Dat, D. T., Huang, W., & Desai, S. (2020). Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply. Vaccine, 38(34), 5418–5423. https://doi.org/10.1016/j.vaccine.2020.06.022

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287474/

Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply


DCVMN Research, Development, and Technology

- DCVMN past supply history
- projected cost 

Factors for Scaling

Filling and finishing is the final stage in the process of vaccine manufacturing and also the most vulnerable to experiencing congestion in production. There are a number of possible solutions for this issue:
-Facilities producing influenza vaccine are likely to have excess capacity for manufacturing
-Adding shifts 
-Companies with a lot of staff and resources are leading the way in building the filling capacity for COVID vaccines
-14 DCVMN members with excess capacity and resources have expressed their capabilities and willingness to tackle surge manufacturing or filling. - --Many members have available resources for formulation and fill-finish.
-Fixing holes in the supply chain



Fill-finish and distribution

About 50 different vaccines for conditions other than COVID-19 are produced or distributed by members of the DCVMN.

Learn Before

Related

Learn After